Compound ID | 3388
9MW1411
Class: Antibody
| Agent Type: | Indirect acting; Antibody; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Binds and neutralizes Staphylococcus aureus alpha-toxin |
| Target Pathogen: | Active against Staphylococcus aureus |
| Description: | Monoclonal antibody (IgG1 mAb); reduces bacterial load and prolongs survival in infection models of bacteraemia and pneumoniae by Staphylococcus aureus |
| Institute where first reported: | Mabwell (Shanghai) Bioscience Co. |
| Year first mentioned: | 2021 |
| Highest developmental phase: | Phase 2 (NCTC04784312) |
| Development status: | Unknown |
| External links: | |
| Citation: | https://doi.org/10.1016/j.ijantimicag.2023.107075 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.